Vorobyeva A

Family name	Vorobyeva
Given name	Anzhelika
Initials	A
ORCID	ORCID 0000-0002-4778-3909
Affiliations	Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

15 publications

PubMed DOI Crossref

Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).

Bezverkhniaia E, Kanellopoulos P, Abouzayed A, ..., Tolmachev V, Orlova A

Int J Mol Sci 24 (24) - [2023-12-12; online 2023-12-12]

PubMed DOI Crossref

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.

Xu T, Schulga A, Konovalova E, ..., Tolmachev V, Vorobyeva A

Int J Mol Sci 24 (3) - [2023-02-02; online 2023-02-02]

PubMed DOI Crossref

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis.

Liu Y, Güler R, Liao Y, ..., Tolmachev V, Frejd FY

Pharmaceutics 14 (11) - [2022-11-19; online 2022-11-19]

PubMed DOI Crossref

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.

Rinne SS, Yin W, Borras AM, ..., Orlova A, Gräslund T

Biomedicines 10 (6) - [2022-05-31; online 2022-05-31]

PubMed DOI Crossref

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.

Yin W, Xu T, Altai M, ..., Gräslund T, Orlova A

Pharmaceutics 13 (11) - [2021-11-21; online 2021-11-21]

PubMed DOI Crossref

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers.

Rinne SS, Leitao CD, Abouzayed A, ..., Löfblom J, Orlova A

Cancers (Basel) 13 (19) - [2021-09-24; online 2021-09-24]

PubMed DOI Crossref

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.

Xu T, Vorobyeva A, Schulga A, ..., Tolmachev V, Deyev SM

Cancers (Basel) 13 (16) - [2021-08-04; online 2021-08-04]

PubMed DOI Crossref

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.

Deyev SM, Xu T, Liu Y, ..., Tolmachev V, Vorobyeva A

Cancers (Basel) 13 (14) - [2021-07-17; online 2021-07-17]

PubMed DOI Crossref

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.

Vorobyeva A, Bezverkhniaia E, Konovalova E, ..., Deyev S, Tolmachev V

Molecules 25 (20) - [2020-10-14; online 2020-10-14]

PubMed DOI Crossref

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.

Vorobyeva A, Konovalova E, Xu T, ..., Tolmachev V, Deyev S

Int J Mol Sci 21 (9) - [2020-05-07; online 2020-05-07]

PubMed DOI Crossref

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.

Rinne SS, Xu T, Dahlsson Leitao C, ..., Tolmachev V, Vorobyeva A

Int J Mol Sci 21 (4) - [2020-02-15; online 2020-02-15]

PubMed DOI Crossref

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3.

Vorobyeva A, Schulga A, Konovalova E, ..., Tolmachev V, Deyev SM

Sci Rep 9 (1) 9405 [2019-06-28; online 2019-06-28]

PubMed DOI Crossref

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.

Rosestedt M, Andersson KG, Rinne SS, ..., Tolmachev V, Orlova A

Sci Rep 9 (1) 6779 [2019-05-01; online 2019-05-01]

PubMed DOI Crossref

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.

Dahlsson Leitao C, Rinne SS, Mitran B, ..., Löfblom J, Orlova A

Int J Mol Sci 20 (5) - [2019-03-02; online 2019-03-02]

PubMed DOI Crossref

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.

Altai M, Leitao CD, Rinne SS, ..., Löfblom J, Orlova A

Cells 7 (10) - [2018-10-11; online 2018-10-11]